EP1645

EP1645 is a radiopharmaceutical imaging agent developed by Biotectid GmbH for the detection and monitoring of joint inflammation in patients with rheumatoid arthritis (RA). It consists of a Fab fragment of a monoclonal antibody targeting the CD4 receptor, which is expressed on the surface of T-helper cells that infiltrate the synovium during active RA. The fragment is labeled with the radioisotope Technetium-99m (Tc99m), allowing for visualization via scintigraphy or SPECT imaging. By specifically binding to CD4+ cells at sites of inflammation, EP1645 provides a non-invasive method to assess disease activity and distribution across multiple joints simultaneously. This approach aims to improve diagnostic accuracy and facilitate the early evaluation of response to disease-modifying therapies.

Other names

Tc99m-labeled anti-CD4 Fab-fragmentTc-99m-labeled anti-CD4 Fab-fragmentTc 99m-labeled anti-CD4 Fab-fragmentAnti-CD4 mAb-FragmentAnti-CD-4 mAb-FragmentAnti-CD 4 mAb-FragmentTc99m-EP1645Tc-99m-EP1645Tc 99m-EP1645